In this issue:
First-line axitinib for patients with metastatic papillary RCC
Rocapuldencel-T + sunitinib as first-line therapy in patients with metastatic RCC
PROs from the IMmotion151 Trial
Deep learning to distinguish benign from malignant renal lesions based on MRI
Outcomes of patients with metastatic RCC treated with targeted therapy after immunotherapy
Improved survival after CN for metastatic RCC in the immunotherapy era
Survival outcomes for off-label use of adjuvant targeted therapy in high-risk locoregional RCC
Chromosomal deletion of 9p21 is linked to poor prognosis in papillary and clear cell kidney cancer
PAK1 expression determines poor prognosis and immune evasion in metastatic RCC
Please login below to download this issue (PDF)